Home Tags PermaLink

Tag: PermaLink

ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression

The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor regression in preclinical models of...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Femtogenix Signs License Agreement with Iksuda Therapeutics

Iksuda Therapeutics, formerly known as Glythera, confirmed that it has signed a licensing agreement with Femtogenix. The agreement gives Iksuda access to Femtogenix’s therapeutic,...

Glythera and Cancer Research UK Collaborate in the Development of “Next-Gen”...

Cancer Research UK and Glythera, a company developing the "next-gen" antibody-drug conjugates or ADCs have agreed that Glythera receives exclusive, worldwide rights, to the...

Glythera Wins Grant to Develops Portfolio of PermaLink®-based ADCs

Glythera, a UK-based company has won a UK £ 1 million (US $ 1,12 million) Innovate UK grant to fund a new project to...

Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs

Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...